Understanding the diagnosis and treatment options empowered the patient, fostering a sense of control and preparedness. Maintaining a positive mental attitude and aligning with supportive healthcare ...

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The ...

Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 ...

BGB-16673, a BTK degrader, targets relapsed/refractory CLL/SLL, showing promising efficacy in heavily pretreated patients. The FDA's fast track designation aims to expedite drug development for ...

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; and Jennifer Woyach, MD. In this video, Graff ...

The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The indication applies to use of the agent in adults ...

The accelerated approval was based on data from the phase 1/2 BRUIN trial that included a subset of 108 patients with CLL/SLL. The Food and Drug Administration (FDA) has granted accelerated approval ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Credit: Bristol Myers Squibb. The approval was based on data from the phase 1/2 TRANSCEND CLL 004 study, which included adults with relapsed or refractory CLL or SLL after progression on a BTKi and ...

A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic ...